Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:alternativeName |
gptkb:DNL151
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Biogen
gptkb:Denali_Therapeutics |
| https://www.w3.org/2000/01/rdf-schema#label |
BIIB122
|
| gptkbp:intendedUse |
gptkb:Parkinson's_disease
|
| gptkbp:mechanismOfAction |
LRRK2 inhibitor
|
| gptkbp:status |
investigational
|
| gptkbp:target |
LRRK2 protein
|
| gptkbp:bfsParent |
gptkb:DNL151
|
| gptkbp:bfsLayer |
8
|